LakeShore Biopharma Amends Merger Agreement
Ticker: LSBCF · Form: 6-K · Filed: Apr 29, 2026 · CIK: 0001946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma Co., Ltd. (LSBCF) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger-agreement, amendment, foreign-issuer
TL;DR
LAKESHORE BIOPHARMA AMENDS MERGER DEAL - NEW TERMS CONFIRMED 4/29
AI Summary
LakeShore Biopharma Co., Ltd. announced on April 29, 2026, that it has entered into an amended merger agreement. This filing includes a press release and an amendment to the original agreement and plan of merger, indicating a revised deal structure or terms for a previously announced transaction.
Why It Matters
This amended merger agreement could signal changes to the terms, valuation, or timeline of a significant corporate transaction for LakeShore Biopharma, impacting its future operations and shareholder value.
Risk Assessment
Risk Level: medium — Merger agreement amendments can introduce new risks or alter existing ones related to deal completion, financing, or regulatory approvals.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Filer of the 6-K report and party to the merger agreement
- 0001946399 (company) — CIK number for LakeShore Biopharma Co., Ltd.
- April 29, 2026 (date) — Date of the amended merger agreement and filing
FAQ
What specific changes were made to the merger agreement?
The filing indicates an 'AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER, DATED APRIL 29, 2026', suggesting specific modifications to the original terms, though the exact details of these changes are not summarized in the provided text.
What is the nature of the amended merger agreement?
It is an amended agreement and plan of merger, filed as an exhibit to the 6-K report, dated April 29, 2026.
What is the filing type and accession number?
The filing type is a 6-K (Report of foreign issuer), with SEC Accession No. 0001213900-26-048850.
When was the filing accepted by the SEC?
The filing was accepted on April 29, 2026, at 08:12:20.
What is LakeShore Biopharma's business address?
The business address is BUILDING NO. 2, 38 YONGDA ROAD DAXING BIOMEDICAL INDUSTRY PARK DAXING DISTRICT, BEIJING F4 102629.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2026 regarding LakeShore Biopharma Co., Ltd. (LSBCF).